Cabozantinib plus atezolizumab for non-clear cell kidney cancer

In this video interview, Dr Monty Pal from the City of Hope Hospital in California talks about a subset of patients in the COSMIC-021 (cohort 10) with non-clear cell RCC, such as papillary renal cell carcinoma (RCC) and chromophobe RCC.

Response rates exceeded 30%, which are very promising findings compared to TKIs alone. However, not everyone benefits from this approach and it is difficult to predict without biomarkers.

Watch the video interview on Practice Update here

Share this Post!


Related post

  TOP